October 2022 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

(Click on drug name to go to MPR monograph.) IND D CON W/P ITX ADR HS MFR
AVASTIN (Bevacizumab) X         X X  
BOOSTRIX (Tetanus and reduced diphtheria toxoid, acellular pertussis vaccine) X X   X   X  
FIRDAPSE (Amifampridine) X X       X    
IMBRUVICA (Ibrutinib)   X       X    
OXLUMO (Lumasiran) X X   X        
PLAVIX (Clopidogrel [as bisulfate])       X X   X  
RELPAX (Eletriptan [as HBr]) X X X          
ROBINUL (Glycopyrrolate)   X X X X X  
ZEJULA (Niraparib) X       X X  
ZOMIG (Zolmitriptan) X X          
Review more drug monograph updates